Trial Profile
An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Naquotinib (Primary) ; Erlotinib; Gefitinib
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLAR
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 09 May 2019 Primary endpoint (Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR)) has not been met, according to the results published in the Annals of Oncology.
- 09 May 2019 Results of the interim analysis, published in the Annals of Oncology